<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.114265</article-id><article-id pub-id-type="publisher-id">ACM-41868</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210400000_91327711.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  促红细胞生成素和铁剂在激素性股骨头坏死全髋关节置换术中的应用研究
  Application of Erythropoietin and Iron in Total Hip Arthroplasty of Hormonal Osteonecrosis of Femoral Head
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>春辉</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杜</surname><given-names>胜杰</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>韦</surname><given-names>标方</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>临沂市人民医院，山东 临沂</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>青岛大学，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>04</issue><fpage>1214</fpage><lpage>1221</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：观察促红细胞生成素联合静脉铁剂治疗在激素性股骨头坏死患者全髋关节置换术中的有效性及安全性。方法：选取2018年9月至2020年9月在临沂市人民医院股骨头专科符合纳入和排除标准的并需初次行单侧全髋关节置换术的激素性股骨坏死患者100例，入院患者随机分为观察组和对照组两组，各50例。观察组患者在术中应用氨甲环酸(TXA)联合围术期应用EPO和静脉铁剂，对照组仅术中应用TXA。两组术前基本资料差异无统计学意义。对术前、术后血红蛋白变化、红细胞指数、红细胞压积、Harris评分等指标进行评估。结果：两组术前一般情况比较差异无统计学意义(P &gt; 0.05)。两组术前血红蛋白、红细胞压积及Harris评分比较差异无统计学意义(P &gt; 0.05)。治疗组术后第3、5、7天的血红蛋白、红细胞数、红细胞压积比较水平均高于对照组，差异有统计学意义(P &lt; 0.05)；两组患者Harris评分在术后3月比较具有统计学意义(p &lt; 0.05)。结论：促红细胞生成素联合静脉铁剂治疗可安全有效地降低激素性股骨头坏死患者行全髋关节置换术后的贫血机率，促进患者术后功能锻炼及快速康复。
    Objective: To observe the effectiveness and safety of erythropoietin combined with intravenous iron in the treatment of hormonal osteonecrosis of the femoral head in total hip arthroplasty. Methods: A total of 100 patients with hormonal osteonecrosis of the femur who met the inclusion and exclusion criteria in the Femoral Head Specialty of Linyi People's Hospital from September 2018 to September 2020 and required initial unilateral total hip replacement were selected. The admitted patients were randomly divided into observation group and control group, 50 cases in each group. Patients in the observation group received intraoperative tranexamic acid (TXA) combined with perioperative use of EPO and intravenous iron, while the control group received only intraoperative TXA. There was no statistically significant difference in basic data between the two groups before operation. Preoperative and postoperative hemoglobin changes, red blood cells, hematocrit, Harris score and other indicators were evaluated. Results: There was no statistically significant difference in general conditions between the two groups before operation (P &gt; 0.05). There was no significant difference in hemoglobin, hematocrit and Harris score between the two groups before operation (P &gt; 0.05). The comparative levels of hemoglobin, red blood cell count, and hematocrit of the treatment group were higher than those of the control group on the 3rd, 5th, and 7th day after operation, and the difference was statistically significant (P &lt; 0.05); the comparison of Harris score between the two groups at 3 months after operation was statistically significant (P &lt; 0.05). Conclusion: Erythropoietin combined with intravenous iron therapy can safely and effectively reduce the risk of anemia in patients with hormonal osteonecrosis of the femoral head after total hip replacement, and promote postoperative functional exercise and rapid recovery. 
  
 
</p></abstract><kwd-group><kwd>股骨头坏死，促红细胞生成素，氨甲环酸，全髋关节置换术, Osteonecrosis of the Femoral Head</kwd><kwd> Erythropoietin</kwd><kwd> Tranexamic Acid</kwd><kwd> Total Hip Arthroplasty</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：观察促红细胞生成素联合静脉铁剂治疗在激素性股骨头坏死患者全髋关节置换术中的有效性及安全性。方法：选取2018年9月至2020年9月在临沂市人民医院股骨头专科符合纳入和排除标准的并需初次行单侧全髋关节置换术的激素性股骨坏死患者100例，入院患者随机分为观察组和对照组两组，各50例。观察组患者在术中应用氨甲环酸(TXA)联合围术期应用EPO和静脉铁剂，对照组仅术中应用TXA。两组术前基本资料差异无统计学意义。对术前、术后血红蛋白变化、红细胞指数、红细胞压积、Harris评分等指标进行评估。结果：两组术前一般情况比较差异无统计学意义(P &gt; 0.05)。两组术前血红蛋白、红细胞压积及Harris评分比较差异无统计学意义(P &gt; 0.05)。治疗组术后第3、5、7天的血红蛋白、红细胞数、红细胞压积比较水平均高于对照组，差异有统计学意义(P &lt; 0.05)；两组患者Harris评分在术后3月比较具有统计学意义(p &lt; 0.05)。结论：促红细胞生成素联合静脉铁剂治疗可安全有效地降低激素性股骨头坏死患者行全髋关节置换术后的贫血机率，促进患者术后功能锻炼及快速康复。</p></sec><sec id="s2"><title>关键词</title><p>股骨头坏死，促红细胞生成素，氨甲环酸，全髋关节置换术</p></sec><sec id="s3"><title>Application of Erythropoietin and Iron in Total Hip Arthroplasty of Hormonal Osteonecrosis of Femoral Head</title><p>Chunhui Zhao<sup>1</sup>, Shengjie Du<sup>1</sup>, Biaofang Wei<sup>2</sup></p><p><sup>1</sup>Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Linyi People’s Hospital, Linyi Shandong</p><p>Received: Mar. 19<sup>th</sup>, 2021; accepted: Apr. 19<sup>th</sup>, 2021; published: Apr. 26<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/58-1572155x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To observe the effectiveness and safety of erythropoietin combined with intravenous iron in the treatment of hormonal osteonecrosis of the femoral head in total hip arthroplasty. Methods: A total of 100 patients with hormonal osteonecrosis of the femur who met the inclusion and exclusion criteria in the Femoral Head Specialty of Linyi People's Hospital from September 2018 to September 2020 and required initial unilateral total hip replacement were selected. The admitted patients were randomly divided into observation group and control group, 50 cases in each group. Patients in the observation group received intraoperative tranexamic acid (TXA) combined with perioperative use of EPO and intravenous iron, while the control group received only intraoperative TXA. There was no statistically significant difference in basic data between the two groups before operation. Preoperative and postoperative hemoglobin changes, red blood cells, hematocrit, Harris score and other indicators were evaluated. Results: There was no statistically significant difference in general conditions between the two groups before operation (P &gt; 0.05). There was no significant difference in hemoglobin, hematocrit and Harris score between the two groups before operation (P &gt; 0.05). The comparative levels of hemoglobin, red blood cell count, and hematocrit of the treatment group were higher than those of the control group on the 3rd, 5th, and 7th day after operation, and the difference was statistically significant (P &lt; 0.05); the comparison of Harris score between the two groups at 3 months after operation was statistically significant (P &lt; 0.05). Conclusion: Erythropoietin combined with intravenous iron therapy can safely and effectively reduce the risk of anemia in patients with hormonal osteonecrosis of the femoral head after total hip replacement, and promote postoperative functional exercise and rapid recovery.</p><p>Keywords:Osteonecrosis of the Femoral Head, Erythropoietin, Tranexamic Acid, Total Hip Arthroplasty</p><disp-formula id="hanspub.41868-formula40"><graphic xlink:href="//html.hanspub.org/file/58-1572155x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/58-1572155x7_hanspub.png" /> <img src="//html.hanspub.org/file/58-1572155x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>股骨头坏死(Osteonecrosis of the Femoral Head, ONFH)作为骨科临床常见的一种慢性致残性疾病 [<xref ref-type="bibr" rid="hanspub.41868-ref1">1</xref>]。根据病因的不同，ONFH可分为两大类：创伤性与非创伤性，非创伤性ONFH可分为激素性和酒精性两大类。该病趋于年轻化，多见于20~40岁中青年人群 [<xref ref-type="bibr" rid="hanspub.41868-ref2">2</xref>]。早期因症状和体征不明显，容易误诊、漏诊。中、晚期股骨头塌陷造成骨关节炎，具有很高病残率 [<xref ref-type="bibr" rid="hanspub.41868-ref3">3</xref>]。全髋关节置换术(Total hip arthroplasty THA)是其晚期主要治疗方式。在世界范围内，患ONFH的人数每年都在增加。据估计，仅在中国就有812万非创伤性ONFH患者 [<xref ref-type="bibr" rid="hanspub.41868-ref4">4</xref>]，其中激素是导致股骨头坏死的重要原因，而激素性股骨头坏死的患者往往合并免疫系统疾病、血液系统疾病、器官移植等基础病，加之长期服用激素加重了机体凝血–纤溶系统的紊乱，因此采取合理的围术期血液管理就显得尤为重要。</p><p>THA由于手术创伤较大，围术期失血量较多(700~2000 ml)，导致有较高输血率(16%~37%) [<xref ref-type="bibr" rid="hanspub.41868-ref5">5</xref>]。输血率增高给患者带来了一系列的风险，例如发热、增高疾病传染机率、引发术后感染等 [<xref ref-type="bibr" rid="hanspub.41868-ref6">6</xref>]。国内学者通过对20,308例患者资料分析显示髋关节置换术前贫血发生率男性25.6%，女性32.8%，其中在股骨头置换术中男性高达49.4%，女性41.3% [<xref ref-type="bibr" rid="hanspub.41868-ref7">7</xref>]。术前贫血是原发性THA术后围手术期并发症的重要危险因素 [<xref ref-type="bibr" rid="hanspub.41868-ref8">8</xref>]。手术创伤、失血因素、输血因素以及术前贫血及术后贫血的进一步加重，导致THA患者死亡、医疗并发症和意外再次入院的风险显著增加。因此必须采取有效措施纠正THA围术期的贫血，优化围术期血液管理，降低术后感染风险以及并发症的发生。随着快速康复理念的发展，促红细胞生成素(EPO)与铁剂广泛应用于骨科手术中，EPO可以促进红细胞的生成，而铁剂可以在生成红细胞过程中补充铁元素，两者协同促进红细胞合成；氨甲环酸也被广泛证实可以有效降低关节置换术中血液丢失；三者共同作为THA围术期血液管理的重要组成部分。目前在激素性ONFH患者髋关节置换术中尚缺乏相关血液管理研究。</p><p>本次研究目的：在快速康复理念指导下，通过对两组共100例患者临床结果的对比分析，探讨促红细胞生成素与铁剂在激素性ONFH患者围术期应用是否有效降低贫血率，并制定安全有效的围术期血液管理方案。</p></sec><sec id="s6"><title>2. 材料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><sec id="s6_1_1"><title>2.1.1. 纳入标准与排除标准</title><p>纳入标准：激素性ONFH需行THA患者；均为初次、单侧行THA患者；患者同意本次实验，并签署知情同意书；能够配合本次临床治疗及后续的检查或询问的患者。排除标准：既往有血栓形成病史的患者；严重的肝肾功能异常者；术后失血严重需输血治疗的患者。</p></sec><sec id="s6_1_2"><title>2.1.2. 内容与方法</title><p>选取2018年9月至2020年9月在临沂市人民医院股骨头专科符合纳入和排除标准的并需初次行单侧THA的激素性股骨坏死患者100例，入院患者随机分为观察组和对照组两组，各50例。观察组患者在术中应用氨甲环酸(TXA)联合围术期应用EPO和静脉铁剂，对照组仅术中应用TXA，两组患者围术期管理均采用ERAS管理模式。</p></sec></sec><sec id="s6_2"><title>2.2. TXA和EPO及静脉铁剂的用法用量</title><sec id="s6_2_1"><title>2.2.1. TXA的用法用量</title><p>本次研究两组患者术中均应用TXA，采用局部联合静脉滴注给药法，关节置换术前THA 20 mg/kg于切皮前10 min滴注完成，关闭手术切口前局部浸润注射1.5 g TXA。</p></sec><sec id="s6_2_2"><title>2.2.2. EPO与静脉铁剂的用法用量</title><p>观察组中加用促红细胞生成素和静脉铁剂，患者入院完善相关评估后，即开始使用EPO与铁剂，重组人促红细胞生成素(rhEPO)皮下注射10,000 U，隔天一次，直至术后7~14天；蔗糖铁静脉滴注200 mg，每日一次，至术后7~14天。若患者Hb &lt; 70 g/L输血治疗并剔除出组。</p></sec><sec id="s6_2_3"><title>2.3. 手术方法及围术期管理</title></sec><sec id="s6_2_4"><title>2.3.1. 手术方法</title><p>患者均采用椎管内麻醉，麻醉后放置腋垫，头垫，固定维持健侧卧位。对手术部位进行常规消毒，肢端保护。在髋关节处取长约15 cm外侧切口，依次切开皮肤、脂肪和筋膜，沿股骨大转子切断臀中肌前份及臀小肌，使其髋关节囊充分暴露，将其前部关节囊切除，显露髋臼及股骨头，过程中要注意止血。在股骨小转子上1.0 cm处锯断股骨颈，取出截断股骨头，清理髋臼底、关节盂唇，选取合适型号人工髋关节置入，保持外展45˚，前倾10˚~15˚，使用不同规格的髋臼锉将髋臼逐级打磨至渗血良好，清理碎屑，将与其匹配的生物型髋臼假体打入，牢固后放置内衬聚乙烯。暴露出股骨头颈的截骨面，开口器开口，开腔扩髓，使用髓腔锉将髓腔逐级打磨，逐级打磨，将与其匹配的生物型股骨柄假体打入，放置人工股骨头，肢体复位后无撞击，冲洗切口处，清点器材，依次缝合肌肉、筋膜。冲洗伤口，逐级缝合伤口，无菌加压包扎。</p></sec><sec id="s6_2_5"><title>2.3.2. 围术期管理</title><p>两组患者均依照加速康复外科理念在《中国髋、膝关节置换术加速康复——围术期管理策略专家共识》指导下对围术期的病人使用治疗及干预措施，具体见表1 [<xref ref-type="bibr" rid="hanspub.41868-ref9">9</xref>]。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Perioperative treatment and intervention measure</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >围术期处理措施</th></tr></thead><tr><td align="center" valign="middle" >术前</td><td align="center" valign="middle" >术前宣教</td><td align="center" valign="middle" >与患者及家属进行沟通，详尽的介绍手术相关情况，取得病人配合，缓解患者术前紧张，焦虑状态。</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >饮食管理</td><td align="center" valign="middle" >术前4~6 h禁食，2 h禁饮。</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >镇疼</td><td align="center" valign="middle" >术前2 d给予0.2 g塞来昔布；疼痛宣教，消除患者恐惧心理，多模式镇疼。</td></tr><tr><td align="center" valign="middle" >术中</td><td align="center" valign="middle" >麻醉方式</td><td align="center" valign="middle" >均采用腰硬联合麻醉</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >尿管放置</td><td align="center" valign="middle" >不常规放置</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >引流管放置</td><td align="center" valign="middle" >不常规放置</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >控制出血</td><td align="center" valign="middle" >创面及时电凝止血，局部浸润注射TXA。</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >保温措施</td><td align="center" valign="middle" >可控式保温毯，输注液体加温至越38˚。</td></tr><tr><td align="center" valign="middle" >术后</td><td align="center" valign="middle" >患肢保护</td><td align="center" valign="middle" >取外展中立位，穿防旋鞋。</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >术后消肿镇疼</td><td align="center" valign="middle" >静脉镇疼泵联合术后冰消散外敷等，多模式镇疼。</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >抗凝</td><td align="center" valign="middle" >术后6 h给予利伐沙班10 mg qd至术后35 d。</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >功能锻炼</td><td align="center" valign="middle" >术后4 h行股四头肌及踝关节功能锻炼，术后当天下午或24 h内下床行走。</td></tr><tr><td align="center" valign="middle" >出院</td><td align="center" valign="middle" >出院指导</td><td align="center" valign="middle" >根据病人恢复情况，制定个体化的出院指导方案。</td></tr></tbody></table></table-wrap><p>表1. 围手术期治疗及干预措施</p></sec></sec><sec id="s6_3"><title>2.4. 观察指标</title><p>年龄(男/女，例数)，性别(岁)，体质量指数BMI (kg/m<sup>2</sup>)；术前、术后2周、术后3个月Harris评分；(术前、术后第1天、第3天、第5天、第7天)血红蛋白Hb (g/L)、红细胞(&#215;10<sup>12</sup>/L)、红细胞压积Hct (L/L)；术后并发症情况。</p></sec><sec id="s6_4"><title>2.5. 统计学分析</title><p>使用SPSS 22. 0统计软件作为工具，用Kolmogorov Smirnov检验行正态分布检验，对于符合正态分布的计量资料以平均数 &#177; 标准差(&#177;s)表示；两组间手术前后数据比较采用独立样本t检验，组内资料比较采用配对t检验；P &lt; 0.05认为差异具有统计学意义。对于同时满足方差齐性的两样本的比较采用独立样本t检验，采用重复测量方差分析对重复测量资料进行比较；不符合正态分布的计量资料比较采用秩和检验，计数资料用百分率(%)表示，无序资料的比较采用pearson χ<sup>2</sup>检验，等级资料的比较采用等级秩和检验。</p></sec></sec><sec id="s7"><title>3. 临床结果</title><sec id="s7_1"><title>3.1. 基础资料比较</title><p>两组患者都顺利完成手术治疗，术后均获得随访。两组患者在术前血红蛋白、术前红细胞指数、术前红细胞压积、术前Harris评分、年龄、性别、体质量指数等方面差异无明显统计学意义(P &gt; 0.05)，具有可比性。两组比较见表2，表3。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of various experimental indicators of the two groups of patients before operatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >术前血红蛋白</th><th align="center" valign="middle" >术前红细胞</th><th align="center" valign="middle" >术前红细胞压积</th><th align="center" valign="middle" >术前Harris评分</th></tr></thead><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >130.88 &#177; 10.30</td><td align="center" valign="middle" >4.33 &#177; 0.64</td><td align="center" valign="middle" >39.50 &#177; 2.33</td><td align="center" valign="middle" >42.62 &#177; 7.04</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >129.96 &#177; 10.91</td><td align="center" valign="middle" >4.31 &#177; 6.14</td><td align="center" valign="middle" >38.96 &#177; 3.24</td><td align="center" valign="middle" >45.00 &#177; 6.69</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.43</td><td align="center" valign="middle" >7.52</td><td align="center" valign="middle" >0.54</td><td align="center" valign="middle" >−1.73</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.67</td><td align="center" valign="middle" >0.80</td><td align="center" valign="middle" >0.96</td><td align="center" valign="middle" >0.08</td></tr></tbody></table></table-wrap><p>表2. 两组患者术前各项实验指标比较</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Statistics of preoperative conditions of the two groups of patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  rowspan="2"  >例数</th><th align="center" valign="middle"  rowspan="2"  >年龄</th><th align="center" valign="middle"  colspan="2"  >性别</th><th align="center" valign="middle"  rowspan="2"  >术前BMI</th></tr></thead><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >女</td></tr><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >48.00 &#177; 10.08</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >25.40 &#177; 5.57</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >47.54 &#177; 9.07</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >24.59 &#177; 3.83</td></tr><tr><td align="center" valign="middle" >统计量</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >T = −0.37</td><td align="center" valign="middle"  colspan="2"  >F = 0.33</td><td align="center" valign="middle" >T = 3.54</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.81</td><td align="center" valign="middle"  colspan="2"  >0.54</td><td align="center" valign="middle" >0.33</td></tr></tbody></table></table-wrap><p>表3. 两组患者术前各项情况统计表</p></sec><sec id="s7_2"><title>3.2. 两组患者各实验观察指标比较</title><p>对观察组和对照组血红蛋白、红细胞指数、红细胞压积进行术后(术后1天、术后3天、术后5天、术后7天)比较，Harris评分进行术后2周，术后3个月比较，结果见表4~7。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of preoperative and postoperative hemoglobin between the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >术前</th><th align="center" valign="middle" >术后1天</th><th align="center" valign="middle" >术后3天</th><th align="center" valign="middle" >术后5天</th><th align="center" valign="middle" >术后7天</th></tr></thead><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >130.88 &#177; 10.30<sup>b</sup><sup>cde</sup></td><td align="center" valign="middle" >101.54 &#177; 9.06<sup>cde</sup></td><td align="center" valign="middle" >97.36 &#177; 10.67<sup>Cde</sup></td><td align="center" valign="middle" >104.0 &#177; 8.13<sup>De</sup></td><td align="center" valign="middle" >114.76 &#177; 8.13<sup>E</sup></td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >129.96 &#177; 10.91<sup>B</sup><sup>CDE</sup></td><td align="center" valign="middle" >100.62 &#177; 11.03<sup>CDE</sup></td><td align="center" valign="middle" >91.48 &#177; 10.67<sup>DE</sup></td><td align="center" valign="middle" >95.76 &#177; 10.53<sup>E</sup></td><td align="center" valign="middle" >100.00 &#177; 10.07</td></tr></tbody></table></table-wrap><p>表4. 两组患者术前及术后血红蛋白比较</p><p>注：a：与观察组术前比较有统计学意义；b：与观察组术后1天比较有统计学意义；c：与观察组术后3天比较有统计学意义；d：与观察组术后5天比较有统计学意义；e：与观察组术后7天比较有统计学意义。</p><p>A：与对照组术前比较有统计学意义；B：与对照组术后1天比较有统计学意义；C：与对照组术后3天比较有统计学意义；D；与对照组术后5天比较有统计学意义；E：与对照组术后7天比较有统计学意义。</p><p>采用两因素重复测量方差分析方法，经箱线图判断，数据无异常；经Shapiro-Wilk检验各组服从正态分布(P &gt; 0.05)。经Mauchly球性检验W = 0.23，P = 0.00，不符合球形对称条件，后进行自由度调整，时间与组别有交互作用具有统计学意义(F = 101.34, P = 0.00)，两组患者在术前、术后1天比较无统计学意义(F<sub>术后</sub><sub>1</sub><sub>天</sub> = 0.19, P = 0.62)在术后3天、术后5天、术后7天比较具有统计学意义(F<sub>术后</sub><sub>3</sub><sub>天</sub> = 8.2, P = 0.00; F<sub>术后</sub><sub>5</sub><sub>天</sub> = 18.69, P = 0.00; F<sub>术后</sub><sub>7</sub><sub>天</sub> = 61.45, P = 0.00)。两组患者组内比较随着时间推移，血红蛋白改变具有统计学意义。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Comparison of red blood cell index between the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >术前</th><th align="center" valign="middle" >术后1天</th><th align="center" valign="middle" >术后3天</th><th align="center" valign="middle" >术后5天</th><th align="center" valign="middle" >术后7天</th></tr></thead><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >4.33 &#177; 0.64<sup>cde</sup></td><td align="center" valign="middle" >3.61 &#177; 0.57<sup>cde</sup></td><td align="center" valign="middle" >3.54 &#177; 0.55<sup>Cde</sup></td><td align="center" valign="middle" >3.71 &#177; 0.54<sup>De</sup></td><td align="center" valign="middle" >3.89 &#177; 0.53<sup>E</sup></td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >4.31 &#177; 6.14<sup>CDE</sup></td><td align="center" valign="middle" >3.72 &#177; 0.52<sup>CDE</sup></td><td align="center" valign="middle" >3.33 &#177; 0.50<sup>DE</sup></td><td align="center" valign="middle" >3.40 &#177; 0.500<sup>E</sup></td><td align="center" valign="middle" >3.48 &#177; 0.49</td></tr></tbody></table></table-wrap><p>表5. 两组患者红细胞指数比较</p><p>注：a：与观察组术前比较有统计学意义；b：与观察组术后1天比较有统计学意义；c：与观察组术后3天比较有统计学意义；d：与观察组术后5天比较有统计学意义；e：与观察组术后7天比较有统计学意义。</p><p>A：与对照组术前比较有统计学意义；B：与对照组术后1天比较有统计学意义；C：与对照组术后3天比较有统计学意义；D；与对照组术后5天比较有统计学意义；E：与对照组术后7天比较有统计学意义。</p><p>采用两因素重复测量方差分析方法，经箱线图判断，数据无异常；经Shapiro-Wilk检验各组服从正态分布(P &gt; 0.05)。经Mauchly球性检验W = 0.02，P = 0.00，不符合球形对称条件，后进行自由度调整，时间与组别有交互作用具有统计学意义(F = 206.50, P = 0.00)，两组患者在术前、术后1天比较无统计学意义(F<sub>术后</sub><sub>1</sub><sub>天</sub> = −0.96, P = 0.33)在术后3天、术后5天、术后7天比较具有统计学意义(F<sub>术后</sub><sub>3</sub><sub>天</sub> = 2.78, P = 0.00; F<sub>术后</sub><sub>5</sub><sub>天</sub> = 3.05, P = 0.00; F<sub>术后</sub><sub>7</sub><sub>天</sub> = 3.98, P = 0.00)。两组患者组内比较随着时间推移，血红蛋白改变具有统计学意义。</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Comparison of the hematocrit of the two groups of patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >术前</th><th align="center" valign="middle" >术后1天</th><th align="center" valign="middle" >术后3天</th><th align="center" valign="middle" >术后5天</th><th align="center" valign="middle" >术后7天</th></tr></thead><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >39.50 &#177; 2.33<sup>b</sup><sup>cde</sup></td><td align="center" valign="middle" >34.41 &#177; 2.18<sup>cde</sup></td><td align="center" valign="middle" >33.90 &#177; 2.24<sup>Cde</sup></td><td align="center" valign="middle" >36.94 &#177; 2.17<sup>E</sup></td><td align="center" valign="middle" >39.50 &#177; 2.33<sup>b</sup><sup>cde</sup></td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >38.96 &#177; 3.24<sup>B</sup><sup>CDE</sup></td><td align="center" valign="middle" >33.78 &#177; 3.17<sup>CDE</sup></td><td align="center" valign="middle" >32.41 &#177; 3.03<sup>DE</sup></td><td align="center" valign="middle" >33.91 &#177; 2.90</td><td align="center" valign="middle" >38.96 &#177; 3.24<sup>B</sup><sup>CDE</sup></td></tr></tbody></table></table-wrap><p>表6. 两组患者红细胞压积比较</p><p>注：a：与观察组术前比较有统计学意义；b：与观察组术后1天比较有统计学意义；c：与观察组术后3天比较有统计学意义；d：与观察组术后5天比较有统计学意义；e：与观察组术后7天比较有统计学意义。</p><p>A：与对照组术前比较有统计学意义；B：与对照组术后1天比较有统计学意义；C：与对照组术后3天比较有统计学意义；D；与对照组术后5天比较有统计学意义；E：与对照组术后7天比较有统计学意义。</p><p>采用两因素重复测量方差分析方法，经箱线图判断，数据无异常；经Shapiro-Wilk检验各组服从正态分布(P &gt; 0.05)。经Mauchly球性检验W = 0.046，P = 0.00，不符合球形对称条件，后进行自由度调整，时间与组别有交互作用具有统计学意义(F = 381.92, P = 0.00)，两组患者在术前、术后1天比较无统计学意义(F<sub>术后</sub><sub>1</sub><sub>天</sub> = 0.11, P = 0.27)在术后3天、术后5天、术后7天比较具有统计学意义(F<sub>术后</sub><sub>3</sub><sub>天</sub> = 2.78, P = 0.00; F<sub>术后</sub><sub>5</sub><sub>天</sub> = 4.11, P = 0.00; F<sub>术后</sub><sub>7</sub><sub>天</sub> = 5.88, P = 0.00)。两组患者组内比较随着时间推移，血红蛋白改变具有统计学意义。</p><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> Comparison of Harris scores between the two groups of patients in each time perio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >髋数</th><th align="center" valign="middle" >术前</th><th align="center" valign="middle" >术后3个月</th></tr></thead><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >42.62 &#177; 7.04<sup>bc</sup></td><td align="center" valign="middle" >77.72 &#177; 3.91<sup>C</sup></td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >45.00 &#177; 6.69<sup>BC</sup></td><td align="center" valign="middle" >73.92 &#177; 3.84</td></tr></tbody></table></table-wrap><p>表7. 两组患者各时间段Harris评分比较</p><p>注：a：与观察组术前比较有统计意义；b：与观察组术后两周比较有统计意义；c：与观察组术后3个月比较有统计学意义。</p><p>A：与对照组术前比较有统计意义；B：与对照组术后两周比较有统计意义；C：与对照组术后3个月比较有统计学意义。</p><p>采用两因素重复测量方差分析方法，经箱线图判断，数据无异常；经Shapiro-Wilk检验各组服从正态分布(P &gt; 0.05)。经Mauchly球性检验W = 0.37，P = 0.00，不符合球形对称条件，后进行自由度调整，两组患者harris评分；时间与组别有交互作用具有统计学意义(F = 38.51, P = 0.00)，说明时间与组别之间具有交互作用。观察组与对照组术前、术后2周的Harris评分无统计学意义(F<sub>术后</sub><sub>2</sub><sub>周</sub> = −0.60, P = 0.54)；术后3个月比较具有统计学意义(F<sub>术后</sub><sub>2</sub><sub>周</sub> = 3.76, P = 0.00)；同组内，时间因素对Harris评分有统计学意义，随时间推移Harris评分逐渐升高。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>促红细胞生成素(erythropoietin, EPO)：是由肾脏毛细血管细胞生成的一种诱导红细胞生成的糖蛋白。若患者患有贫血等疾病，EPO的合成显著增加。目前利用基因重组技术在体外合成的重组人促红细胞生成素(recombinant human erythropoietin, rhEPO)在骨科领域得到广泛应用，可以改善患者术前贫血，促进术后炎症性贫血恢复 [<xref ref-type="bibr" rid="hanspub.41868-ref10">10</xref>]。越来越多的研究显示围术期使用EPO是安全有效的，临床中EPO常联合铁剂共同应用，一篇共25项随机对照试验累计4159例病例的meta分析显示，在关节置换术围术期联合应用EPO和铁剂可显著改善术后贫血情况 [<xref ref-type="bibr" rid="hanspub.41868-ref11">11</xref>]。EPO在造血功能方面，通过红细胞动员，提高术后血红蛋白水平；在组织修复方面，通过调节体内抗凋亡因子及抗炎性因子的表达，促进骨损伤修复 [<xref ref-type="bibr" rid="hanspub.41868-ref12">12</xref>]。Frew等 [<xref ref-type="bibr" rid="hanspub.41868-ref13">13</xref>] 通过回顾分析发现关节置换患者，围术期给予EPO联合铁剂，髋关节和膝关节置换术的输血率分别从23.0%和6.7%降至4.3%和0.5%。髋关节和膝关节置换术的中位住院时间从6天减少到3天。安帅等 [<xref ref-type="bibr" rid="hanspub.41868-ref14">14</xref>] 通过对149例关节置换患者研究发现，非老年关节置换患者术前贫血率、异体输血率及输血量相比老年患者较低；围术期应用EPO联合铁剂的非老年患者血液管理效果更佳。</p><p>本次实验两组当中均应用TXA，观察组中加用EPO和静脉铁剂，两组患者在手术前其性别、年龄，BMI、血红蛋白、红细胞、红细胞压积比较均无统计学意义。两组间比较术后第1天两组患者的血红蛋白、红细胞及红细胞压积均不具有统计学意义，考虑为人工全髋关节置换术后第一天，应用EPO时间过短，药效还未发挥完全。但在术后3天、术后5天、术后7天两组患者血红蛋白、红细胞指数、红细胞压积比较均具有统计学意义，说明EPO具有提升血红蛋白，加速红细胞生成的作用；两组患者组内在术后1天，术后3天血红蛋白、红细胞、红细胞压积呈下降趋势，并且各组内比较具有统计学意义，考虑原因为人工全髋关节置换为骨科大手术，其创伤大，在手术结束后，手术部位仍有失血情况，但观察组内下降趋势较对照组内变缓，自术后5天起，两组患者血红蛋白、红细胞指数及红细胞压积均呈上升趋势，观察组较对照组上升趋势明显，且两组内各时间比较具有统计学意义；两组患者Harris评分通过重复测量方差分析，时间与组别具有交互作用，两组患者Harris评分在术后3月比较具有统计学意义；组内各时间点比较具有统计学意义。说明EPO联合铁剂可以促进ONFH患者术后的功能恢复。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，因激素性ONFH患者常合并免疫系统疾病、血液系统疾病等基础病，加之又长期大剂量使用激素，身体一般情况及耐受性较差，THA围术期失血量较多，所以激素性ONFH患者围术期的血液管理应较一般关节置换的患者受到更多的重视，EPO联合铁剂治疗，可有效地动员并提高激素性股骨头坏死术前患者的血红蛋白水平，促进患者术后的快速康复，具有显著的临床疗效且具有安全性，值得临床中推广应用。同时本实验尚有不完善之处，两组患者共100例患者，样本量较小，随访的时间较短等。如上所述激素性ONFH围术期血液管理可供选择的方法众多，但尚未形成指南性的共识。作为关节外科医生，关键是充分了解每一种血液管理措施的适应证及优缺点，在术前全面评估患者的病情、贫血耐受性及预测失血量的情况下，根据患者的具体情况制定完善的围术期血液管理方案。</p></sec><sec id="s10"><title>文章引用</title><p>赵春辉,杜胜杰,韦标方. 促红细胞生成素和铁剂在激素性股骨头坏死全髋关节置换术中的应用研究Application of Erythropoietin and Iron in Total Hip Arthroplasty of Hormonal Osteonecrosis of Femoral Head[J]. 临床医学进展, 2021, 11(04): 1214-1221. https://doi.org/10.12677/ACM.2021.114265</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41868-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">中国成人股骨头坏死临床诊疗指南(2020) [J]. 中华骨科杂志, 2020, 40(20): 1365-1376.</mixed-citation></ref><ref id="hanspub.41868-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Moya-Angeler, J., Gianakos, A.L., Lane, J.M., et al. (2015) Current Concepts on Osteonecrosis of the Femoral Head. World Journal of Orthopedics, 6, 590-601. &lt;br&gt;https://doi.org/10.5312/wjo.v6.i8.590</mixed-citation></ref><ref id="hanspub.41868-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Choi, H.R., Steinberg, M.E. and Cheng, E.Y. (2015) Osteonecrosis of the Femoral Head: Diagnosis and Classification Systems. Current Reviews in Musculoskeletal Medicine, 8, 210-220. &lt;br&gt;https://doi.org/10.1007/s12178-015-9278-7</mixed-citation></ref><ref id="hanspub.41868-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, D., Zhang, F., Qin, L., et al. (2020) Guidelines for Clinical Diagnosis and Treatment of Osteonecrosis of the Femoral Head in Adults (2019 Version). Journal of Orthopaedic Translation, 21, 100-110.  
&lt;br&gt;https://doi.org/10.1016/j.jot.2019.12.004</mixed-citation></ref><ref id="hanspub.41868-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Mart, P., Maczynski, A., Baulot, E., et al. (2017) Total Hip Arthroplasty with Dual Mobility Cup in Osteonecrosis of the Femoral Head in Young Patients: Over Ten Years of Follow-Up. International Orthopaedics, 41, 605-610.  
&lt;br&gt;https://doi.org/10.1007/s00264-016-3344-7</mixed-citation></ref><ref id="hanspub.41868-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Pierce, T.P., Elmallah, R.K., Mont, M.A., et al. (2015) Outcomes of Total Hip Arthroplasty in Patients with Osteonecrosis of the Femoral Head: A Current Review. Current Reviews in Musculoskeletal Medicine, 8, 246-251.  
&lt;br&gt;https://doi.org/10.1007/s12178-015-9283-x</mixed-citation></ref><ref id="hanspub.41868-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">周宗科, 翁习生, 邱贵兴, 等. 中国骨科手术加速康复——围术期血液管理专家共识[J]. 中华骨与关节外科杂志, 2017, 10(1): 1-7.</mixed-citation></ref><ref id="hanspub.41868-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Grosso, M.J., Boddapati, V., Neuwirth, A.L., et al. (2020) The Effect of Preoperative Anemia on Complications after Total Hip Arthroplasty. The Journal of Arthroplasty, 35, S214-S218. &lt;br&gt;https://doi.org/10.1016/j.arth.2020.01.012</mixed-citation></ref><ref id="hanspub.41868-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">周宗科, 翁习生, 裴福兴, 等. 中国髋、膝关节置换术加速康复——围术期管理策略专家共识[J]. 中华骨与关节外科杂志, 2016, 9(1): 1-9.</mixed-citation></ref><ref id="hanspub.41868-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Lin, D.M., Lin, E.S. and Tran, M.H. (2013) Efficacy and Safety of Erythropoietin and Intravenous Iron in Perioperative Blood Management: A Systematic Review. Transfusion Medicine Reviews, 27, 221-234.  
&lt;br&gt;https://doi.org/10.1016/j.tmrv.2013.09.001</mixed-citation></ref><ref id="hanspub.41868-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Li, Y., Yin. P., Tang, P., et al. (2018) A Meta-Analysis and Systematic Review Evaluating the Use of Erythropoietin in Total Hip and Knee Arthroplasty. Therapeutics and Clinical Risk Management, 14, 1191-1204.  
&lt;br&gt;https://doi.org/10.2147/TCRM.S159134</mixed-citation></ref><ref id="hanspub.41868-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">郑少强, 周雁, 王庚, 等. 促红细胞生成素在骨科手术围术期的应用[J]. 骨科临床与研究杂志, 2019, 4(6): 377-379.</mixed-citation></ref><ref id="hanspub.41868-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Frew, N., Alexander, D., Acornley, A., et al. (2016) Impact of a Blood Management Protocol on Transfusion Rates and Outcomes Following Total Hip and Knee Arthroplasty. Annals of the Royal College of Surgeons of England, 98, 380-386. &lt;br&gt;https://doi.org/10.1308/rcsann.2016.0139</mixed-citation></ref><ref id="hanspub.41868-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">安帅, 李佳义, 李征, 等. 促红细胞生成素对不同年龄关节置换患者围术期贫血的影响[J]. 实用骨科杂志, 2020, 26(8): 688-692.</mixed-citation></ref></ref-list></back></article>